BioCentury
ARTICLE | Company News

Celltech, Abgenix in SLAM deal

February 6, 2001 8:00 AM UTC

Celltech (LSE:CCH; CLL) received rights to use ABGX's SLAM (Selected Lymphocyte Antibody Method) technology for rapid selection in vitro of high affinity antibodies. Under the deal, CCH has a license ...